Copyright
©The Author(s) 2018.
World J Transplant. Feb 24, 2018; 8(1): 13-22
Published online Feb 24, 2018. doi: 10.5500/wjt.v8.i1.13
Published online Feb 24, 2018. doi: 10.5500/wjt.v8.i1.13
Table 1 Pathologies leading to renal disease and transplantation
Underlying disease | Group A (n = 44) | Group B (n = 41) |
Glomerulonephritis | 10 | 6 |
Nephroangiosclerosis | 6 | 7 |
Polycystic kidney disease | 8 | 10 |
End-stage kidney disease | 10 | 5 |
Alport syndrome | 2 | 2 |
IgA nephropathy | 6 | 0 |
Nephrotic syndrome | 2 | 0 |
Multicystic renal dysplasia | 0 | 4 |
Interstitial nephritis | 0 | 2 |
Haemolytic uraemic syndrome | 0 | 4 |
Vasculitis polyangiitis | 0 | 1 |
Table 2 Immunosuppressive and other therapies in both groups
Tacrolimus | Cyclosporine | Steroid therapy | Purine synthesis inhibitors | (mTOR) inhibitors | Anti-hypertensive therapy | Beta-blockers | Insulin therapy | Statin | Ezetimibe | |
Group A, n = 44 | 28 (64%) | 12 (27%) | 35 (80%) | 33 (75%) | 7 (16%) | 33 (75%) | 18 (14%) | 1 (2%) | 14 (34%) | 2 (5%) |
Group B, n = 41 | 27 (66%) | 10 (24%) | 30 (73%) | 34 (83%) | 5 (12%) | 30 (73%) | 18 (44%) | 2 (5%) | 18 (41%) | 2 (5%) |
Table 3 Mean ± SD of exercise capacity and blood chemistry
Group A (n = 44) | Group B (n = 41) | |||||
T0 | T6 | T12 | T0 | T6 | T12 | |
Maximum workload (W) | 95 ± 36 | 107 ± 38a | 108 ± 41c | 102 ± 32 | 102 ± 30 | 98 ± 34 |
V’O2 peak (mL/kg per minute) | 22.8 ± 8.3 | 25.6 ± 9.0a | 25.9 ± 7.5c | 21.6 ± 6.8 | 22.6 ± 6.6 | 21.5 ± 6.4 |
HR max (bpm) | 142 ± 24 | 142 ± 22 | 145 ± 22c | 133 ± 22 | 134 ± 23 | 131 ± 22 |
Diastolic BP at rest (mmHg) | 80 ± 8 | 80 ± 8 | 78 ± 6 | 81 ± 9 | 82 ± 8 | 82 ± 8 |
Diastolic BP at V’O2 peak (mmHg) | 85 ± 11 | 83 ± 12 | 82 ± 13 | 84 ± 10 | 81 ± 13 | 80 ± 11 |
Diastolic BP at 3’ recovery (mmHg) | 75 ± 9 | 76 ± 8 | 75 ± 9 | 78 ± 10 | 79 ± 9 | 78 ± 8 |
Systolic BP at rest (mmHg) | 126 ± 14 | 126 ± 12 | 125 ± 11 | 130 ± 16 | 126 ± 15 | 127 ± 13 |
Systolic BP at V’O2 peak (mmHg) | 183 ± 26 | 183 ± 21 | 185 ± 25 | 181 ± 26 | 181 ± 27 | 178 ± 30 |
Systolic BP at 3’ recovery (mmHg) | 128 ± 17 | 129 ± 14 | 131 ± 16 | 136 ± 16 | 136 ± 21 | 135 ± 20 |
Body mass index (kg/m2) | 24.1 ± 4.3 | 24.0 ± 4.3 | 23.6 ± 4.5c | 25.5 ± 4.4 | 25.3 ± 4.0 | 25.8 ± 4.5 |
Fat mass (%) | 21.1 ± 9.0 | 19.8 ± 8.3a | 20.7 ± 7.9 | 20.0 ± 7.8 | 18.9 ± 6.5 | 19.8 ± 8.1 |
Aerobic threshold workload (W) | 53 ± 23 | 60 ± 29 | 60 ± 27 | 53 ± 21 | 62 ± 27 | 57 ± 25 |
Aerobic threshold HR (bpm) | 113 ± 20 | 108 ± 19 | 112 ± 18 | 103 ± 16 | 103 ± 19 | 103 ± 16 |
Anaerobic threshold workload (W) | 84 ± 30 | 94 ± 37 | 91 ± 31c | 89 ± 32 | 97 ± 38 | 88 ± 36 |
Anaerobic threshold HR (bpm) | 131 ± 21 | 130 ± 23 | 134 ± 18c | 125 ± 20 | 125 ± 21 | 120 ± 19e |
Knee extensors right (kg) | 87 ± 38 | 93 ± 40 | 98 ± 39 | 55 ± 27 | 61 ± 26 | 60 ± 24 |
Knee extensors left (kg) | 80 ± 36 | 93 ± 40 | 95 ± 42 | 51 ± 23 | 60 ± 25 | 58 ± 23 |
Plantar flexors right (kg) | 70 ± 34 | 76 ± 29 | 82 ± 27c | 62 ± 35 | 69 ± 27 | 65 ± 23 |
Plantar flexors left (kg) | 70 ± 33 | 77 ± 29 | 79 ± 28 | 64 ± 34 | 71 ± 24 | 67 ± 24 |
Counter movement jump (cm) | 24.0 ± 10.0 | 26.4 ± 10.2 | 25.9 ± 9.3c | 21.5 ± 9.4 | 22.9 ± 10.2 | 20.9 ± 10.2 |
Handgrip right (kg) | 30.8 ± 13.1 | 33.2 ± 12.2 | 32.3 ± 11.9c | 36.3 ± 9.5 | 35.9 ± 9.8 | 34.2 ± 9.6 |
Handgrip left (kg) | 29.3 ± 13.6 | 30.7 ± 11.7 | 30.6 ± 11.7c | 35.1 ± 9.3 | 34.4 ± 9.7 | 32.7 ± 10.2 |
Elbow flexors Right (kg) | 8.8 ± 2.7 | 9.4 ± 2.8 | 9.7 ± 2.8 | 8.0 ± 3.4 | 9.4 ± 3.1e | 9.4 ± 3.5 |
Elbow flexors Left (kg) | 8.7 ± 3.2 | 9.6 ± 3.4 | 9.6 ± 3.1 | 7.3 ± 3.4 | 8.6 ± 2.7e | 8.7 ± 3.5 |
Elbow extensors right (kg) | 5.8 ± 2.0 | 6.5 ± 2.3 | 6.9 ± 2.3 | 5.1 ± 2.2 | 6.1 ± 2.1e | 6.0 ± 2.1 |
Elbow extensors left (kg) | 5.7 ± 2.0 | 6.5 ± 2.4 | 6.8 ± 2.4 | 4.9 ± 2.3 | 5.6 ± 1.8e | 5.7 ± 1.9 |
Shoulder abductors (kg) | 5.3 ± 2.2 | 6.3 ± 2.5 | 6.4 ± 2.3 | 4.2 ± 2.7 | 5.2 ± 2.1e | 5.4 ± 2.7 |
Creatinine (mg/dL) | 1.26 ± 0.38 | 1.27 ± 0.41 | 1.21 ± 0.29 | 1.37 ± 0.48 | 1.32 ± 0.50 | 1.42 ± 0.47 |
eGFR (mL/min per 1.73 m2) | 59.4 ± 19.3 | 58.0 ± 19.6 | 62.6 ± 21.8 | 56.3 ± 21.2 | 58.1 ± 17.8 | 52.9 ± 17.4 |
Proteinuria (g/24 h) | 0.41 ± 0.51 | 0.34 ± 0.46 | 0.52 ± 0.63 | 0.45 ± 0.57 | 0.48 ± 0.59 | 0.61 ± 0.44 |
Haemoglobin (g/dL) | 12.8 ± 1.8 | 12.3 ± 1.7 | 12.6 ± 1.6 | 12.1 ± 1.8 | 12.5 ± 1.9 | 12.8 ± 1.5 |
Triglycerides (mg/dL) | 122 ± 42 | 117 ± 41 | 117 ± 47 | 138 ± 69 | 131 ± 57 | 132 ± 59 |
Cholesterol (mg/dL) | 196 ± 37 | 186 ± 52 | 200 ± 43 | 195 ± 33 | 193 ± 31 | 188 ± 34 |
Table 4 Mean ± SD of 36-Item Short Form Health Survey questionnaire scales
Group A (n = 44) | Group B (n = 41) | |||||
T0 | T6 | T12 | T0 | T6 | T12 | |
Physical function | 84 ± 20 | 91 ± 11a | 92 ± 12c | 89 ± 10 | 86 ± 20 | 86 ± 23 |
Role physical | 83 ± 25 | 88 ± 21 | 96 ± 15c | 91 ± 19 | 91 ± 19 | 86 ± 24 |
Bodily pain | 80 ± 24 | 80 ± 22 | 89 ± 20 | 86 ± 19 | 84 ± 22 | 84 ± 22 |
General health | 63 ± 20 | 67 ± 21 | 68 ± 20 | 64 ± 21 | 67 ± 19 | 66 ± 17 |
Vitality | 67 ± 16 | 70 ± 15 | 69 ± 19 | 67 ± 18 | 69 ± 14 | 68 ± 14 |
Social function | 75 ± 19 | 80 ± 20 | 83 ± 17c | 82 ± 19 | 78 ± 21 | 78 ± 21 |
Role emotional | 85 ± 24 | 91 ± 20 | 90 ± 22 | 93 ± 16 | 96 ± 15 | 93 ± 17 |
Mental health | 75 ± 16 | 75 ± 16 | 74 ± 19 | 74 ± 18 | 77 ± 16 | 74 ± 16 |
- Citation: Roi GS, Mosconi G, Totti V, Angelini ML, Brugin E, Sarto P, Merlo L, Sgarzi S, Stancari M, Todeschini P, La Manna G, Ermolao A, Tripi F, Andreoli L, Sella G, Anedda A, Stefani L, Galanti G, Di Michele R, Merni F, Trerotola M, Storani D, Nanni Costa A. Renal function and physical fitness after 12-mo supervised training in kidney transplant recipients. World J Transplant 2018; 8(1): 13-22
- URL: https://www.wjgnet.com/2220-3230/full/v8/i1/13.htm
- DOI: https://dx.doi.org/10.5500/wjt.v8.i1.13